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Cancers result from the accumulation of genetic lesions, but the
cellular consequences of driver mutations remain unclear, espe-
cially during the earliest stages of malignancy. The V617F mutation
in the JAK2 non-receptor tyrosine kinase (JAK2V617F) is present as
an early somatic event in most patients with myeloproliferative
neoplasms (MPNs), and the study of these chronic myeloid
malignancies provides an experimentally tractable approach to
understanding early tumorigenesis. Introduction of exogenous
JAK2V617F impairs replication fork progression and is associated
with activation of the intra-S checkpoint, with both effects
mediated by phosphatidylinositide 3-kinase (PI3K) signaling. Anal-
ysis of clonally derived JAK2V617F-positive erythroblasts from
MPN patients also demonstrated impaired replication fork pro-
gression accompanied by increased levels of replication protein
A (RPA)-containing foci. However, the associated intra-S check-
point response was impaired in erythroblasts from polycythe-
mia vera (PV) patients, but not in those from essential
thrombocythemia (ET) patients. Moreover, inhibition of p53 in
PV erythroblasts resulted in more gamma-H2Ax (γ-H2Ax)–marked
double-stranded breaks compared with in like-treated ET erythro-
blasts, suggesting the defective intra-S checkpoint function seen in
PV increases DNA damage in the context of attenuated p53 signal-
ing. These results demonstrate oncogene-induced impairment of
replication fork progression in primary cells from MPN patients,
reveal unexpected disease-restricted differences in activation of
the intra-S checkpoint, and have potential implications for the
clonal evolution of malignancies.
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Next-generation sequencing studies are starting to reveal thegenetic complexity of tumors but are limited in their ability
to infer the details of antecedent clonal evolution (1, 2). It remains
unclear how mutations accrue in the early stages of tumor forma-
tion, how preneoplastic cells respond to DNA damage, and how
these events potentiate secondary transformation.
The myeloproliferative neoplasms (MPNs) provide a powerful
model for investigating mechanisms of mutation accumulation
and disease acceleration. They encompass a spectrum of chronic
myeloid malignancies characterized by overproduction of mor-
phologically normal cells of the myeloerythroid lineages and
include polycythemia vera (PV) and essential thrombocythemia
(ET) (3, 4). Several aspects of MPNs make them useful in the
investigation of clonal evolution: they reflect subtle modulation
of hematopoiesis and are often diagnosed after an incidental
blood count, thus providing investigators a glimpse of the earliest
stages of tumorigenesis; these disorders are experimentally
tractable, as hematopoietic progenitors are readily cultured from
peripheral blood of MPN patients and are amenable to clonal
analysis; and PV and ET patients have near-normal life expec-
tancy, thus permitting serial biological sampling over many years.
A majority of PV and ET patients harbor a V617F mutation
in the JAK2 non-receptor tyrosine kinase (JAK2V617F) that
activates downstream signaling and is associated with cytokine-
independent growth (5–8). Moreover, several studies have
demonstrated that JAK2V617F is associated with increased DNA
damage. Mutant JAK2 inhibits Bcl-xL deamidation and the apo-
ptotic response to DNA damage in primary cells from patients
with PV, providing a potential mechanism for accumulation of
DNA damage (9). JAK2V617F expression leads to increased
frequency of γH2Ax-marked double-stranded breaks (DSBs)
(10, 11), mutations of the HPRT gene locus (12), and sponta-
neous homologous recombination events (13). Increased DSB
repair was also observed in CD34+ hematopoietic cells obtained
from JAK2V617F-positive PV and myelofibrosis patients (12).
However, the molecular basis for JAK2V617F-mediated DNA
damage remains poorly understood.
Replication-associated errors are one of the largest endogenous
sources of DSBs and are particularly problematic for cells har-
boring oncogenes that stimulate S-phase entry under inappropriate
circumstances, such as limiting levels of nutrients (14). This can
promote stalling of the replisome during DNA replication, a phe-
nomenon called “replication stress.” Stalled forks that collapse can
generate single-strand DNA nicks (15, 16), which can in turn be
converted to DSBs if a replication fork subsequently attempts to
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replicate past the nick (17). The intra-S checkpoint guards against
such replication-induced genomic damage by stabilizing stalled
forks and, in the absence of appropriate repair, promoting se-
nescence or apoptosis. Activation of the intra-S checkpoint is
therefore an important defense against transformation (18).
In this article we explore the effect of JAK2V617F on DNA
replication and S-phase checkpoint function.
Results
JAK2V617F Expression Causes Replication Stress. To investigate
whether JAK2V617F influences DNA replication, BJ human
diploid fibroblasts were engineered to express wild-type JAK2 or
JAK2V617F (hereafter referred to as BJWT and BJV617F, re-
spectively). Western blotting confirmed ectopic expression of JAK2
in both BJWT and BJV617F lines compared with parental BJ cells (SI
Appendix, Fig. S1A). Expression of JAK2V617F protein was
somewhat lower than that of wild-type JAK2 protein but was
consistently associated with increased activation of downstream
signaling, as indicated by increased phosphorylation of STAT1,
STAT5, and AKT (SI Appendix, Fig. S1A).
Chromosome combing permits visualization and analysis of
replication tracts on individual, BrdU-labeled DNA fibers (Fig.
1A). Using this approach, we quantified several aspects of DNA
replication in the JAK2-expressing BJ fibroblasts. First, 355 in-
dividual replication fork structures were scored to differentiate
among “origins of replication,” “normally progressing forks,”
and “stalled forks.” JAK2V617F expression had no effect on
frequency of origin firing. However, we observed a significant
increase in the proportion of stalled forks (as defined by a >30%
reduction in the length of the tract labeled by the second labeling
pulse compared with the first pulse) in BJV617F cells compared
with BJWT cells (23% versus 5%, respectively; P < 0.05) (Fig. 1B
and SI Appendix, Fig. S1B). It is worth noting that this analysis is
likely to underestimate the actual frequency of fork stalling, as
only forks that stall during the second labeling step would be
scored. Second, replication fork processivity was assessed, as it
is another indicator of fork stalling. We observed a significant
decrease in the mean replication rate, going from 1.5 ± 0.04 Kb/min
(n = 110) in BJWT cells to 0.80 ± 0.04 Kb/min (n = 65) in BJV617F
cells (P < 0.0001) (Fig. 1C). Third, as two replication forks
emerging bidirectionally from the same origin tend to exhibit the
same replication rate, replication stress can be intimated by the
presence of asymmetric progression of the two outgoing forks.
We therefore analyzed all origin structures to compare the
length of their left and right replication tracts and used the
ratio of >0.7 between left and right forks to represent sym-
metric progression (19). Replication origins displayed increased
asymmetry in BJV617F cells compared with BJWT cells (Fig. 1D). In
BJWT cells, the mean ratio between left and right forks was 0.99 ±
0.2 (n = 18), with only 6% of the replication bubbles showing
asymmetric dynamics, whereas in BJV617F cells, the mean ratio
was 1.24 ± 0.4 (n = 19), with 58% of the origins showing
asymmetry. Taken together, these data demonstrate that
JAK2V617F causes increased replication fork stalling.
JAK2V617F Expression Activates the Intra-S Checkpoint. The check-
point protein Chk1 is phosphorylated at Ser345 (pS345-Chk1) in
response to stalled replication forks, and it is also the principle
mediator of the intra-S checkpoint response. Levels of pS345-
Chk1 were increased in BJV617F cells relative to BJWTcells (Fig.
1E and SI Appendix, Fig. S1C). This was associated with longer
doubling times for BJV617F cells compared with BJWT cells (Fig.
1F), a difference that did not reflect increased apoptosis (Fig. 1G).
Instead, BJV617F cells exhibited a delayed exit from S and entry
into M, as shown by synchronizing cells at the G1/S border with
mimosine, followed by release into standard growth medium (Fig.
1H). Together, these data demonstrate that JAK2V617F-induced
replication stress is associated with the activation of an intra-S
checkpoint and prolongation of S-phase duration.
We next investigated which signaling pathways were necessary
for the effect of JAK2V617F on replication stress. Levels of
phosphorylated Chk1 were assessed after transient transfection
of JAK2-expressing BJ fibroblasts with pools of siRNAs (three to
five siRNAs per pool) targeting STAT1, STAT5, or the p85
catalytic subunit of phosphatidylinositide 3-kinase (PI3K). Effi-
cient knockdown of corresponding protein species was con-
firmed by immunoblot (SI Appendix, Fig. S2 A and B). In BJV617F
cells, knockdown of PI3K, but not STAT1 or STAT5, reduced
pS345-Chk1 to a level comparable to that of BJWT cells (Fig.
2A). To ensure the siRNA pools were not generating off-target
effects, each pool was deconvoluted and three individual siRNAs
were transfected into BJ cells. All three individual siRNAs tar-
geting PI3K abrogated pS345-Chk1 levels in BJV617F cells,
whereas none of the individual STAT1 or STAT5 siRNAs did (Fig.
2B). Furthermore, treatment of BJV617F cells with the PI3K in-
hibitor PI103 also led to decreased Chk1 phosphorylation (SI Ap-
pendix, Fig. S3A) accompanied by reduced AKT phosphorylation
(SI Appendix, Fig. S3B).
It remained formally possible that the reduced Chk1 phos-
phorylation after PI3K knockdown was a phenomenon in-
dependent of fork stalling. To investigate this possibility, we also
performed chromosome combing on JAK2-expressing BJ fibro-
blasts after siRNA knockdown of STAT1, STAT5, and PI3K.
Consistent with the Chk1 phosphorylation results, we observed
that increased fork stalling (Fig. 2C), decreased fork rate (Fig.
2D), and increased origin asymmetry (SI Appendix, Fig. S4) were
Fig. 1. JAK2V617F induces replication fork stalling and activates the intra-S
checkpoint in BJ human diploid fibroblasts. (A) Replication structures of
single combed DNA molecules from BJWT and BJV617F cells labeled with IdU
(red) and CldU (green), showing origins of replication (Orig), progressing
forks (Prog), and stalled forks (Stall). (B) Scoring of fibers for different fork
structures from BJWT and BJV617F cells. Fibers from each slide were scored by
two independent observers. The data represent the mean ± SD of three
independent experiments. (C) Quantitation of fork rate from BJWT and
BJV617F cells. Results represent the mean ± SD for 110 fibers from BJWT cells
and 65 fibers from BJV617F cells. (D) Origin symmetry in BJWT and BJV617F cells.
Each point represents a single origin, with the length of one arm (arbitrarily
designated as “left”) plotted relative to its opposite moving counterpart
(designated as “right”). The dotted line represents a ratio of 0.7 between
the two arms. (E) Analysis of pS345-CHK1 levels in BJWT and BJV617F cells by
intracellular flow cytometry. The results are representative of four experi-
ments. (F–H) Analysis of doubling time (F), cell death (G), and S-phase du-
ration (H) of BJWT and BJV617F cells. (B–D) Testing for significance was
performed using an unpaired t test (C and D) or a one-sample t test (E). *P <
0.05; **P < 0.01; ***P < 0.001. WT, wild-type.































only mitigated in cells transfected with siRNAs targeting PI3K,
not STAT1 or STAT5. Collectively, these results indicate that
the PI3K pathway is an important mediator of JAK2V617F-
induced replication stress and intra-S checkpoint activation.
Replication Stress Is a Feature of JAK2 V617F-Positive Erythroblasts
from MPN Patients. The results described here demonstrate that
exogenous JAK2V617F causes replication stress in fibroblasts.
We next investigated whether a similar phenomenon operates in
primary JAK2-mutant cells obtained from MPN patients. To this
end, we studied clonally pure populations of JAK2V617F-het-
erozygous cells together with autologous JAK2-wild-type cells
obtained from the same patient (Fig. 3A). This strategy controls
for differences in sex, age, therapy, constitutional genetic
background, and other confounding variables (20). Cells from
a given patient were pooled by genotype and subjected to
chromosome combing.
We scored 1,163 individual DNA fibers obtained from six
MPN patients (three ET, three PV). Compared with autologous
JAK2-wild-type cells, JAK2-mutant cells from both ET and PV
patients exhibited increased frequencies of stalled forks (Fig.
3B), slower fork processivity (Fig. 3C), and greater replication
origin asymmetry (Fig. 3D). Culturing colonies in the presence of
the STAT5 inhibitor pimozide (SI Appendix, Fig. S5A) or the
STAT1 inhibitor fludarabine (SI Appendix, Fig. S5B) did not
abrogate fork stalling and processivity in JAK2-mutant colonies
(SI Appendix, Fig. S5 D and E). In contrast, culturing JAK2-
mutant colonies in the presence of PI103 reduced fork stalling
and processivity to their normal levels (Fig. 3 E and F and SI
Appendix, Fig. S5C). These findings accord with our fibroblast
data and represent, to our knowledge, the first demonstration of
replication stress induced by an oncogenic tyrosine kinase in
primary patient samples.
Impaired Intra-S Checkpoint in PV. To investigate whether
JAK2V617F-induced replication stress is associated with a de-
tectable expression signature, we reanalyzed expression array
data from clonally derived JAK2-mutant and JAK2-wild-type
cells obtained from 36 MPN patients (20 ET, 16 PV) (20).
Gene set enrichment analysis revealed that genes regulated by
exposure to UV light were enriched among genes differentially
expressed in mutant cells from ET patients (SI Appendix, Fig.
S6A and Table S1). In addition, connectivity map analysis was
applied to JAK2-mutant gene signatures to look for similarities
to gene expression modulations induced by various pharmaco-
logic agents. Expression changes in JAK2-mutant cells from ET
patients were similar to those observed in cell lines treated with
the topoisomerase inhibitors camptothecin or irinotecan (SI
Appendix, Fig. S6 B and C and Table S2). UV light, campto-
thecin, and irinotecan share the common attribute of interfering
with DNA replication, so these data are consistent with our
results demonstrating replication stress in JAK2-mutant cells
from ET patients. In marked contrast, JAK2-mutant cells from
PV patients displayed no enrichment for UV-regulated gene sets
or for genes modulated in response to camptothecin or irinote-
can (SI Appendix, Fig. S6D and Tables S3 and S4). Because
replication stress was observed in JAK2-mutant cells from
patients with ET, as well as those with PV, these data suggest the
possibility of a defective response to replication stress in PV.
To explore this hypothesis, intracellular flow cytometry was
performed on autologous wild-type and JAK2V617F-heterozygous
erythroblasts from 16 MPN patients (seven ET and nine PV) to
Fig. 2. JAK2V617F-induced fork stalling is PI3K-dependent. (A and B)
pS345-CHK1 levels in BJWT and BJV617F cells after transfection with scrambled
siRNA control (scr) or either pools of three to five siRNAs targeting STAT1,
STAT5, or the p85 subunit of the PI3K (PIK3CA) (A) or individual siRNAs
targeting STAT1, STAT5, or PIK3CA (B). (C and D) BJWT and BJV617F cells
transfected with control siRNA or siRNAs targeting STAT1, STAT5, or PIK3CA
were scored for frequency of origin (O), normal progressing forks (P), or
stalled forks (S) (C) or fork rate (D). (A–D) Data represent the mean ± SD of
three independent experiments. Testing for significance was performed
using an unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001. WT, wild-type.
Fig. 3. JAK2V617F causes replication fork stalling in primary MPN patient
samples. (A) Strategy for analysis of paired normal and JAK2V617F samples
from MPN patients. (B) Scoring of fibers for structures resembling origins
(Orig), progressing (Prog), or stalled (Stall) forks from erythroblasts from PV
and ET patients. (C and D) Measurement of fork rate (C) and origin sym-
metry (D) in wild-type and JAK2-heterozygous erythroblasts from ET and PV
patients. (E) Scoring of fork structures in control and PI103-treated wild-type
and mutant erythroblasts. The results represent the mean ± SD for three
MPN patients (one PV, two ET). (F) Fork rates of control and PI103-treated
wild-type and mutant erythroblasts. The results represent the mean ± SD for
three MPN patients (one PV, two ET). (B–F) The data are represented as
mean ± SD. Each patient’s fibers were scored by two independent observers.
Testing for statistical significance was performed using an unpaired t test or
a one-sample t test. *P < 0.05; **P < 0.01; ***P < 0.001. WT, wild-type.





















quantify pS345-pChk1 levels. Relative to autologous wild-type
erythroblasts, mean pS345-Chk1 levels were higher in JAK2-
mutant erythroblasts from ET patients compared with those
from PV patients (Fig. 4 A and B). We also assessed Chk1 ac-
tivity in the hematopoietic stem and progenitor cell compart-
ment of normal individuals and JAK2-mutant MPN patients.
Higher levels of pS345-Chk1 were also observed in the cycling
fraction of peripheral blood CD34+ cells from ET patients
compared with PV patients (SI Appendix, Fig. S7 A–C). These
data accord with our findings in erythroblasts and demonstrate
that differential Chk1 phosphorylation is also seen in the he-
matopoietic stem and progenitor cell compartment.
To investigate the mechanism for impaired Chk1 phosphory-
lation in JAK2-mutant PV erythroblasts, we performed immu-
nocytochemistry on 1,034 individual nuclei from seven MPN
patients (three ET and four PV) to assess the formation of foci
containing replication protein A (RPA) and Ataxia telangiecta-
sia and Rad3 related (ATR), two checkpoint proteins critical for
the recognition of stalled replication forks and signaling to Chk1.
Relative to wild-type erythroblasts, median RPA focus formation
was significantly increased in JAK2-mutant cells, a phenomenon
common to both ET and PV patients (Fig. 4C). This finding is
consistent with a role for RPA in marking sites of exposed single-
stranded DNA at stalled fork intermediates. No significant dif-
ference was observed in the number of RPA foci in JAK2-mutant
cells of ET and PV patients (Fig. 4C and SI Appendix, Fig.
S8A), suggesting stalled replication forks had similar stability in
the two diseases. Consistent with this, direct staining for single-
stranded DNA by flow cytometry also showed increased levels of
single-stranded DNA in mutant erythroblasts in all patients, but
no difference between ET and PV patients (SI Appendix, Fig. S9
A and B). In contrast, patterns of ATR foci differed significantly
between PV and ET. In all three ET patients tested, JAK2-
mutant cells harbored increased numbers of ATR foci, the ma-
jority of which colocalized with RPA foci, whereas there was no
increase in the number of ATR foci in JAK2-mutant cells from
four PV patients (Fig. 4C and SI Appendix, Fig. S8A). Moreover,
a significant reduction in the numbers of nuclei exhibiting more
than 20 RPA-ATR colocalizing foci was observed in JAK2-
mutant erythroblasts from patients with PV relative to those with
ET (SI Appendix, Fig. S10A). Real-time quantitative PCR
revealed no differences in levels of ATR transcript between
mutant erythroblasts of ET and PV patients (SI Appendix, Fig.
S11). In addition, RPA-ATR colocalizing loci were readily
detected in BJ fibroblasts expressing JAK2V617F, but not in
wild-type JAK2 (SI Appendix, Fig. S12), suggesting that the lack
of ATR foci formation represents an acquired deficit in PV
patients. Collectively, these findings demonstrate that there is
impaired physical recruitment of ATR to sites of stalled repli-
cation forks in JAK2-mutant erythroblasts from PV, which
accounts for impaired Chk1 phosphorylation in response to
JAK2V617F-mediated replication stress.
We next assessed whether JAK2V617F-positive cells from PV
patients were able to respond to camptothecin, a potent inducer
of replication stress. Although camptothecin treatment yielded
robust ATR foci and RPA-ATR colocalizing foci in wild-type
erythroblasts, this response was significantly blunted in JAK2-
mutant erythroblasts (Fig. 4D and SI Appendix, Fig. S8B).
Moreover, compared with autologous JAK2-wild-type erythroblasts,
fewer JAK2-mutant erythroblasts developed more than 20
colocalizing foci after camptothecin treatment (SI Appendix,
Fig. S10B). When grown in camptothecin, compared with
autologous wild-type erythroid burst forming units (BFU-Es) or
ET-derived JAK2-mutant BFU-Es, JAK2-mutant PV BFU-Es
exhibited less apoptosis (Fig. 4E), more cells in S/G2/M (Fig.
4F), and increased colony size (Fig. 4G). Collectively, these
findings demonstrate that in patients with PV, JAK2V617F-
positive cells display impaired activation of the intra-S check-
point and that this is associated with sustained proliferation and
survival, despite replication stress.
p53 Inhibition Increases DNA Damage in PV. To assess the effect of
impaired intra-S checkpoint function on genomic integrity in ET
and PV patients, we performed immunocytochemistry on erythro-
blasts from six MPN patients (three ET and three PV) to assess
the formation of γ-H2Ax-labeled foci, which mark the sites of
DSBs. We found a significant increase in the number of γ-H2Ax-
positive foci in mutant erythroblasts cultured under normal
growth conditions (Fig. 5 A and B), a finding common to both
ET and PV patients. However, no significant difference in the
numbers of γ-H2Ax-positive foci was observed between the two
diseases (Fig. 5 A and B). These data indicate that mutant JAK2
expression is associated with increased DNA damage, but dif-
ferential intra-S checkpoint activity is not associated with further
increased frequency of DNA damage in chronic phase disease.
The lack of disparity in DNA damage between ET and PV
(despite differential activation of the intra-S checkpoint) may be
a result of the presence of intact p53 pathways downstream of
the intra-S checkpoint to guard against genomic instability.
Consistent with this idea, we detected activation of the p53 pathway
Fig. 4. Disease-specific impairment of intra-S checkpoint activity. (A) Ex-
emplary intracellular phospho-flow cytometry of pS345-CHK1 expression in
autologous wild-type and V617F-heterozygous BFU-E colonies from ET and
PV patients. (B) Dot plot depicting ratio of pCHK1 MFI in JAK2-mutant
erythroblasts relative to autologous wild-type erythroblasts from seven ET
and nine PV patients. (C) Immunofluorescent staining of cytospins from wild-
type and V617F-heterozygous BFU-E pools from PV and ET patients for RPA
(red), ATR (green), and DAPI (blue). The bar graphs depict median foci
number per cell from three ET and four PV patients. (D) RPA, ATR, and DAPI
staining of cytospins from wild-type and V617F-heterozygous BFU-E pools
from PV patients grown in 4 nM camptothecin. Bar graph depicts data from
four PV patients. (E–G) Effect of camptothecin treatment on cell death (E),
cell proliferation (F), and colony size (G). For proliferation and cell death, the
data are depicted as a normalized fold change relative to the untreated
wild-type sample for each disease group. The results represent the mean ±
SD for five ET and three PV patients. (B–G) Testing for statistical significance
was performed using a Student t test. *P < 0.05; **P < 0.01; ***P < 0.001.
WT, wild-type.































in mutant erythroblasts from both ET and PV patients; mutant
erythroblasts exhibited heightened levels of phosphorylated p53
protein (SI Appendix, Fig. S13A) and increased expression of two
p53 target genes: CDKN1A (which encodes the p21 protein) and
TP53I3 (SI Appendix, Fig. S13B). We therefore next assessed
whether inhibiting the p53 pathway would have differential
effects on the accumulation of DNA damage in ET- versus PV-
derived erythroblasts. To inhibit p53 signaling, pifithrin-alpha
(PFT-α) was used, which has been described to specifically pre-
vent transactivation of p53-responsive genes (21). Strikingly, PV
JAK2-mutant cells cultured in the presence of PFT-α exhibited
a significant increase in the number of γ-H2Ax foci compared
with autologous wild-type cells or ET-derived JAK2-mutant cells
under identical conditions (Fig. 5 A and B). This was not asso-
ciated with alterations in the frequency of apoptosis (Fig. 5C),
proliferation (Fig. 5D), or colony size (Fig. 5E), suggesting these
DNA damage-laden cells can persist in vitro. Cumulatively, these
data suggest that the p53 pathway plays a key role in maintaining
genomic stability during chronic-phase MPN and that its in-
hibition in the context of an impaired intra-S checkpoint (as in
PV patients) leads to increased DNA damage without affecting
cell survival or proliferation.
Discussion
Cancers evolve as a consequence of the stepwise accumulation of
genetic lesions with subclonal evolution. However, the cellular
consequences that flow from the acquisition of a driver mutation
are poorly understood, particularly in the early stages of tumor
development. Here we demonstrate that JAK2V617F increases
the frequency of replication fork stalling. As JAK2 mutations
arise early during MPN evolution and may represent initiating
events in a significant proportion of MPN patients (22, 23), these
findings support the hypothesis that replication stress is among
the earliest events in tumorigenesis. This concept is consistent
with observations in other early premalignant conditions, such as
dysplastic epithelia (24) and precursor lung lesions (25, 26), in
which activation of checkpoint kinases was used as a surrogate
for fork stalling and was assessed in bulk populations of
cells. Furthermore, we have performed chromosome combing on
clonally derived and genotyped populations of primary cells from
MPN patients. To our knowledge, our data represent the first
direct demonstration of replication fork stalling in primary cells
from any malignancy.
Several models have been proposed to explain how different
oncogenes induce replication stress. Overexpression of the hu-
man papillomavirus E6/E7 oncoproteins and cyclin E drives
transition from G1 to S phase under inappropriate circum-
stances, such as limiting levels of nutrients (14), and H-RasV12
causes increased activation of dormant origins and rereplication
(26). Our data, however, preclude both of these mechanisms for
JAK2V617F. We observe that wild-type and mutant-JAK2
expressing fibroblasts entered S phase at similar rates. Moreover,
the frequency of origin structures was similar in both wild-type
and mutant-JAK2-expressing fibroblasts and patient-derived
colonies, arguing against activation of dormant origins. Instead,
our results show that JAK2V617F causes replication fork stalling
by activating the PI3K signaling pathway. Indeed, analogous
findings have been reported in Saccharomyces cerevisiae, in which
increased growth factor signaling and AKT activity are associ-
ated with replication stress (27), but a similar correlation has not
previously been reported in metazoans. It is unclear how in-
creased AKT activity perturbs replication dynamics. However, it
may be relevant that AKT phosphorylation of epigenetic regu-
lators such as EZH2 and p300 histone deacetylase can result in
unscheduled euchromatinization during S-phase, with the en-
suing interference between the transcription and replication
machineries causing replication fork stalling (28, 29). In addi-
tion, AKT may directly destabilize the replication fork through
phosphorylation of the DNA methyltransferase DNMT1, thus
impairing its retention at the replication fork (30).
Our data also demonstrate that some MPN patients, especially
those with PV, exhibit an attenuated intra-S checkpoint response
to the presence of JAK2V617F. This observation is unlikely to
reflect constitutional genetic differences between PV and ET
patients, as autologous JAK2-wild-type colonies were used as
controls. Moreover, wild-type colonies from both patient groups
exhibited normal patterns of RPA and ATR foci after campto-
thecin exposure. Instead, our evidence suggests the existence of
additional genetic or epigenetic events that modulate intra-S
checkpoint activity in most PV patients and in rare ET patients.
A recent survey of the mutational landscape of MPN patients did
not reveal any recurrent mutations in intra-S checkpoint regu-
lators in PV patients (31), although many of the lesions identi-
fied in PV patients have not been functionally characterized with
respect to their ability to modulate the intra-S checkpoint.
How might impairment of the intra-S checkpoint response
relate to MPN biology? PV and ET are distinguished primarily
by the enhanced erythrocytosis seen in PV, which is thought to
reflect increased STAT5 and/or reduced STAT1 activity (20, 32,
33). However, our data demonstrate that reduced activity of
STAT5 or STAT1 did not influence Chk1 activation, replication
fork stalling, or rate of fork progression. Instead, it seems more
plausible that the reduced intra-S checkpoint response seen in
PV patients may contribute to increased genomic instability. This
mechanism might contribute to the increased prevalence of
JAK2V617F homozygosity observed in PV patients, although
when assessed at a clonal level, the prevalence of JAK2V617F
homozygosity is only modestly increased in PV patients (34).
Moreover, the concept that a reduced intra-S checkpoint gives
rise to enhanced DNA damage runs counter to evidence that the
genomes of PV patients are generally stable; exome sequencing
revealed a median of only 6.5 somatic mutations per patient for
both ET and PV (31), and cytogenetic lesions are infrequent
(35). We also found that JAK2-mutant cells from ET and PV
patients have similar frequencies of DSBs, which is in agreement
with other studies that suggest ET and PV are not significantly
different with respect to genomic stability (35).
So what is the biological significance of impaired intra-S check-
point in PV? We observed activated p53 signaling in JAK2-mutant
Fig. 5. Loss of p53 activity increases DNA damage in PV JAK2-mutant cells.
(A) Representative immunocytochemical micrographs of γ-H2Ax (green) and
DAPI (blue) staining of cytospins from wild-type and V617F-heterozygous
BFU-E pools from PV and ET patients cultured in the presence of DMSO
vehicle or 10 nM PFT-α. (B) Histogram depicts median γ-H2Ax foci per cell for
three ET and three PV patients cultured with and without PFT-α. Testing for
statistical significance was performed using a Student t test. *P < 0.05; **P <
0.01. (C–E) Effect of PFT-α treatment on cell death (C), cell proliferation (D),
and colony size (E). For proliferation and cell death, the data are depicted as
a normalized fold change relative to the untreated wild-type sample for
each disease group. The results represent the mean ± SD for three ET and
three PV patients. WT, wild-type.





















erythroblasts, indicating that p53-dependent processes initiated
downstream of JAK2V617F-induced replication stress may be
crucial in maintaining the genome stability of ET and PV.
Indeed, p53 mutations are common in MPN patients who
transform to AML (36), and p53-deficient secondary AML
exhibits high rates of cytogenetic abnormalities (37). We there-
fore hypothesized that impaired intra-S checkpoint function
could synergize with p53 loss to exacerbate genomic instability
during leukemic transformation. Strikingly, when cultured in the
presence of p53 inhibitors, PV JAK2-mutant cells had signifi-
cantly more DSBs compared with ET-derived counterparts. Our
data are consistent with murine studies that have shown that Atr
haploinsufficient mice only develop genomic aberrations and
malignant phenotypes after further compromise of DNA repair
checkpoints, such as through loss of p53 function (38). More-
over, a recent study showed a higher frequency of copy number-
neutral loss-of-heterozygosity in leukemic blasts from individuals
who had an antecedent PV compared with those who had an
antecedent ET (39). Co-occurrence of the JAK2V617F mutation
with copy number-neutral loss-of-heterozygosity was also asso-
ciated with poorer prognosis (39). Although this study was lim-
ited to unmatched samples and needs to be reproduced in
a larger cohort, it is consistent with the idea that defective intra-S
checkpoint activity seen in PV patients is associated with
heightened genomic instability during leukemic transformation,
and possibly even a decrease in overall survival.
The prognosis of leukemias with an antecedent MPN phase
is exceedingly poor. The selection for clones with impaired
DNA damage repair checkpoints may contribute to clonal evo-
lution and the well-recognized recalcitrance of these advanced
malignancies to respond to therapy with genotoxic agents. Fur-
ther understanding of the aberrant DNA repair processes in these
disorders may facilitate the development of synthetic lethal or other
therapeutic approaches to these treatment-refractory malignancies.
Materials and Methods
Chromosome Combing. For chromosome combing, at least 1 × 106 BJ cells or
five colonies of each genotype were pooled and resuspended in StemSpan
Serum-Free Expansion Medium (SFEM) supplemented with 30% (vol/vol)
FBS, 50 μg/mL stem cell factor, 3 U/mL erythropoietin, and 40 ng/mL in-
sulin-like growth factor-1. Replicating DNA was first labeled with 25 μM
5-iodo-2′-deoxyuridine (IdU; Sigma), followed by 250 μM 5-chloro-2′-
deoxyuridine (ClDU; Sigma) for 20 min each. Cells were then harvested,
genomic DNA was extracted, and individual DNA molecules were stretched
on glass slides, stained with anti-IdU (1:300) and anti-CldU (1:150), and
analyzed under oil immersion on a Zeiss Axioscop 2 fluorescent micro-
scope. Methodology for calculating fork stalling, origin symmetry, and
fork rate are described in the SI Appendix, Materials and Methods. Addi-
tional information on all other experimental protocols also is provided in
the SI Appendix, Materials and Methods.
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